New Frontier: COVID-19 Crisis Opens Door For Dexcom, Abbott To Bring CGMs Into Hospitals For First Time
Dexcom and Abbott’s permission by US regulators to bring their continuous glucose monitoring devices directly to hospitals for remote monitoring of COVID-19 patients could open up a new market opportunity post-pandemic.
You may also be interested in...
Full steam ahead: Dexcom brings its flagship G6 CGM to veterans, creates first registry for in-hospital use and signs collaboration with University of Virginia.
FreeStyle Libre 2 is the only integrated continuous glucose monitoring system that continuously measures the user's blood glucose without fingersticks.
Dexcom expects 2020 revenues to reach $1.85bn driven by new patient adoption of its CGM device, but will not launch its next-gen G7 this year.